These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 9182159)
1. [A scientist's day-dream or future reality? Specific immunotherapy against cancer]. Kiessling R; Kärre K Lakartidningen; 1997 Apr; 94(17):1595-600. PubMed ID: 9182159 [No Abstract] [Full Text] [Related]
2. Cancer immunotherapy--dream or reality? Nossal GJ Aust J Ophthalmol; 1973 Oct; 1(3):95-100. PubMed ID: 4548844 [No Abstract] [Full Text] [Related]
3. [Cancer immunotherapy: immunologic bases, reality and hopes]. Dietrich PY; Farace F; Caignard A; Escudier B; Triebel F Bull Cancer; 1993 Jul; 80(7):584-600. PubMed ID: 8204939 [TBL] [Abstract][Full Text] [Related]
4. Cancer vaccines: pessimism in check. Mocellin S; Mandruzzato S; Bronte V; Marincola FM Nat Med; 2004 Dec; 10(12):1278-9; author reply 1279-80. PubMed ID: 15580242 [No Abstract] [Full Text] [Related]
5. [Immunotherapy for cancer--modern immunologic strategies in oncology]. Halama N; Zoernig I; Jäger D Dtsch Med Wochenschr; 2008 Oct; 133(41):2105-8. PubMed ID: 18985564 [TBL] [Abstract][Full Text] [Related]
6. Effects of the tumor microenvironment on the efficacy of tumor immunotherapy. Neeson P; Paterson Y Immunol Invest; 2006; 35(3-4):359-94. PubMed ID: 16916758 [TBL] [Abstract][Full Text] [Related]
7. [Technological advances in immuno-oncology: from fundamental concepts to patient immunological monitoring]. Chouaib S; Echchakir H; Angevin E; Guerra N; Kosmatopoulos K; Caignard A; Lim A; Baron V; Ferradini L; Mami-Chouaib F Bull Cancer; 2001 Aug; 88(8):733-40. PubMed ID: 11578941 [TBL] [Abstract][Full Text] [Related]
8. Tumor vaccine: current trends in antigen specific immunotherapy. Baral R Indian J Exp Biol; 2005 May; 43(5):389-406. PubMed ID: 15900903 [TBL] [Abstract][Full Text] [Related]
9. Cyclins against cancer: a novel family of tumor antigens? Klein-González N; Kondo E; von Bergwelt-Baildon MS Immunotherapy; 2010 Sep; 2(5):595-7. PubMed ID: 20874640 [No Abstract] [Full Text] [Related]
10. [Molecular mechanisms of tumor and immune system interaction]. Berezhnoĭ AE; Gnuchev NV; Georgiev GP; Kozlov AM; Larin SS Vopr Onkol; 2008; 54(6):669-83. PubMed ID: 19241839 [No Abstract] [Full Text] [Related]
11. Cellular and humoral immune responses of cancer patients to defined tumor antigens. Jäger D; Jäger E; Bert F; Knuth A Cancer Chemother Biol Response Modif; 2001; 19():385-93. PubMed ID: 11686025 [No Abstract] [Full Text] [Related]
12. [Molecular targets for development of cancer immunotherapy]. Kawakami Y Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828 [No Abstract] [Full Text] [Related]
13. [Oncoimmunology: some fundamental problems of cancer immunotherapy]. Nedospasov SA; Kuprash DV Mol Biol (Mosk); 2007; 41(2):355-68. PubMed ID: 17514902 [TBL] [Abstract][Full Text] [Related]
14. [Discovery of the splicing of peptides by the proteasome and study of preclinical models of anticancer immunotherapy]. Van den Eynde B Bull Mem Acad R Med Belg; 2007; 162(5-6):352-6. PubMed ID: 18405005 [TBL] [Abstract][Full Text] [Related]
17. [Identification of cancer antigens of relevance for specific cancer immunotherapy]. van den Eynde B Bull Mem Acad R Med Belg; 2001; 156(10-12):548-55. PubMed ID: 12371273 [TBL] [Abstract][Full Text] [Related]
18. Immune monitoring of cancer patients undergoing experimental immunotherapy. Shankar G; Salgaller ML Curr Opin Mol Ther; 2000 Feb; 2(1):66-73. PubMed ID: 11249653 [TBL] [Abstract][Full Text] [Related]
19. Progress in human tumour immunology and immunotherapy. Rosenberg SA Nature; 2001 May; 411(6835):380-4. PubMed ID: 11357146 [TBL] [Abstract][Full Text] [Related]